

AtriCure Announces Commencement of Public Offering of Common Stock

The Associated Press

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan 15, 2013--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole manager for the offering.

AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital.

This offering will be made pursuant to a prospectus supplement to AtriCure's prospectus, dated July 20, 2011, filed as part of AtriCure's effective \$50 million shelf registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com.

About AtriCure, Inc. AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage. The Company believes cardiothoracic surgeons are adopting its ablation products for the treatment of AF during concomitant open-heart surgical procedures and sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke. The FDA has not cleared or approved certain AtriCure products for the treatment of AF or a reduction in the risk of stroke.

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience

AtriCure Announces Commencement of Public Offering of Common Stock

Published on Medical Design Technology (<http://www.mdtmag.com>)

and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: AtriCure, Inc.

Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com or Investor Relations Contact: Westwicke Partners Lynn
Pieper, 415-202-5678 Lynn.pieper@westwicke.com KEYWORD: UNITED STATES
NORTH AMERICA OHIO INDUSTRY KEYWORD: SENIORS WOMEN SURGERY HEALTH
CARDIOLOGY HOSPITALS MEDICAL DEVICES RESEARCH FDA CONSUMER SCIENCE
MEN SOURCE: AtriCure, Inc. Copyright Business Wire 2013 PUB: 01/15/2013 04:04
PM/DISC: 01/15/2013 04:04 PM
<http://www.businesswire.com/news/home/20130115006702/>

Source URL (retrieved on 11/28/2014 - 7:46am):

http://www.mdtmag.com/news/2013/01/atricure-announces-commencement-public-offering-common-stock?qt-most_popular=0&qt-recent_content=0